26 results about "Ileum" patented technology

A composition for use in a method of providing sustained energy release over time in a subject is described. The composition comprises or consists of microparticles comprising high glycaemic index (GI) carbohydrate contained within a gastric-resistant, ileal-sensitive, GLP-1 stimulative, non-porous carrier configured for release of the high GI carbohydrate in the ileum, wherein the composition is administered orally to the subject.

The utility model belongs to the technical field of colon lavage devices, and discloses a smooth colon lavage device which comprises an infusion bag, a liquid guide pipeline is arranged at the bottom end of the infusion bag, a first connecting assembly is arranged between the infusion bag and the liquid guide pipeline, and a valve is installed at the end, close to the infusion bag, of the liquid guide pipeline. A liquid guide tip is arranged at the end, away from the infusion bag, of the liquid guide pipeline, a second connecting assembly is arranged between the liquid guide pipeline and the liquid guide tip, and the first connecting assembly comprises a first connecting pipeline, a first threaded groove and a first external thread. Compared with a traditional enema bag which is poor in direct lavage effect and poor in comfort level, the device has the advantages that the lavage effect is improved, the use experience of a patient is remarkably improved, and risks and discomfort in the operation process are reduced.

The application discloses a compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and a preparation method thereof, relates to the technical field of livestock and poultry intestinal tract health regulation, and comprises microcapsule particles with a multilayer structure, which sequentially comprises a core layer, a first coating layer, an intermediate functional layer and a second coating layer; the compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and the preparation method thereof are characterized in that the preparation is arranged as a multilayer microcapsule structure composed of the core layer, the first coating layer, the intermediate functional layer and the second coating layer in sequence, and the first coating layer and the second coating layer adopt enteric polymers with different pH dissolution ranges, so that the intermediate functional layer can be released first in the pH environment from the duodenum to the jejunum, and the core layer is released subsequently in the pH environment of the ileum, thereby realizing the graded and zoned release of active components of plant essential oils in the front and rear sections of the small intestine of laying hens, and matching different essential oil components with the barrier repair requirements of each section of the intestinal tract.

The invention discloses a drainage self-closing device for preventive ileum fistulization, relates to an ileum fistulization device, and aims to solve the problem that the conventional preventive ileum fistulization method needs a secondary operation. The device comprises a Y-shaped drainage tube, a water injection tube, an air injection tube, a purse string, a suture line, a knot pushing rod and a suture needle, wherein a bag receiving hole is formed in the side wall of the inlet end of the Y-shaped drainage tube, and the tube wall of the outlet end of the Y-shaped drainage tube is a T-shaped tube wall; the end part of the gas injection tube is a balloon; the knot pushing rod is a hollow pipe, a lower hole is formed in the lower end of the pipe, and a wire outlet hole is formed in the side wall of the pipe close to the lower hole; and an inclined plate plug is arranged at the upper part of the wire outlet hole in the hollow pipe. The device is used for fistulization, healing of the fistulization opening is accelerated, and the device can be used for clinical medicine, in particular to the field of gastrointestinal surgery.

The invention relates to the technical field of animal feed processing, and particularly discloses a pig feed and a processing method thereof.The pig feed comprises a cereal raw material, a protein raw material, an energy supplementing raw material, a mineral raw material, a vitamin and microelement premix and two-phase fermented corn particles, wherein the two-phase fermented corn granules are composed of a delayed release granule core containing fermented corn, lipid, a pH sensitive polymer coating layer and a quick release outer layer containing fermented corn, so that a part of a fermentation product is quickly released in the gastric segment, and the other part of the fermentation product is delayed to be released in the rear segment of the small intestine, especially in the ileum region, so as to realize targeted regulation and control on ileum flora. Compared with daily ration only adopting common fermented corn, the processing method has the advantages that the growth performance is kept, the ratio of ileum lactic acid bacteria to escherichia coli can be more effectively increased, the intestinal health is improved, the emission of ammonia gas and hydrogen sulfide in excrement is further reduced, and the processing method has remarkable nutrition regulation and control and environment-friendly effects.

The application belongs to the technical field of biological medicine, and particularly relates to application of a CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation. The application provides application of the CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation, wherein a nucleotide sequence of the CLIC5 gene is shown as SEQ ID NO:1. The application finds that intestinal epithelial cell-specific knockout of the CLIC5 can reduce a serum endotoxin level, improve intestinal epithelial barrier function, increase a content of butyric acid, reduce a serum inflammatory factor level, and also reduce a gene expression level of an inflammatory factor in an ileum and a colon. The application first discloses that intestinal epithelial cell-specific knockout of the CLIC5 can effectively prevent or treat intestinal inflammation and reduce a body inflammatory factor level, thereby providing a new target and method for treating human intestinal inflammation.

A stoma plug suitable for controlling the output of biological fluids from a colon, ileum and / or ureter through a stoma created by a colostomy, ileostomy or urostomy, respectively. The stoma plug includes a tube comprising an opening in a proximal portion and at least one opening in a distal portion, a two-way valve system including a base element and a plug, the two-way valve system connected to the tube through the base element, the two-way valve system configured to control the fluid flow through the opening of the proximal portion of the tube, and a cap configured to cover the two-way valve system and the stoma, the cap including an opening to directly access the two-way valve system from the outside. The tube is configured to be inserted into the colon, ileum and / or ureter through its distal portion, and the two-way valve system is configured to passively remain closed and to be opened when the plug is displaced from the at least one opening

The utility model relates to a leather bridge loop type ileum stoma drainage device, which belongs to the technical field of ileum stoma and comprises a collecting box, an air supply box and an abdominal wall, a connecting pipe is inserted in the right side of the collecting box, a connecting assembly is arranged on the outer side of the connecting pipe, and an observation box is fixedly communicated with the right side of the connecting pipe. The right side of the observation box fixedly communicates with a hose, the bottom of the air supply box communicates with an air outlet pipe, the right side of the air outlet pipe communicates with an air bag, and a locking assembly is arranged on the inner side of the air bag. According to the leather bridge loop type ileum stoma drainage device, through the arrangement of the connecting assembly, the collecting box and the connecting pipe can be disassembled easily, the device can be cleaned easily after being used, the use convenience of the device can be improved easily, through the arrangement of the locking assembly, adjustment between the air bag and the hose is achieved, and therefore the drainage requirements of different intestinal tracts are met; the use flexibility of the device is improved, and the whole device is convenient to clean, high in flexibility and convenient to use.

This invention provides a process for preparing ileal-targeted empty capsules, relating to the field of pharmaceutical excipients technology. The process includes the following steps: preparing the following raw materials: gelatin, titanium dioxide, and sodium stearate; dissolving the gelatin in water at 60-70°C, heating and stirring, adding titanium dioxide and sodium stearate, mixing well, and allowing to stand to obtain a film-forming gel. This invention utilizes a preparation mechanism involving the mixing of water-soluble polyacrylic acid resin IV, polyacrylic acid resin III, and polyvinyl alcohol, with the remaining materials added in steps, to achieve the predetermined goal of ileal disintegration. Furthermore, based on the synergistic effect of polyacrylic acid resin III with water-soluble polyacrylic acid resin IV and polyvinyl alcohol, the drug release rate of the empty capsule is improved, allowing the drug to rapidly reach an effective concentration in the ileum and exert its therapeutic effect more effectively.

The present invention relates to a pH responsive polymer composition for the enteric coating of hard shell capsules, which composition is suitable for the delivery of pharmaceutical dosage forms, in particular microbiota, to the ileum and colon. The pH responsive polymer composition comprises at least one anionic poly (meth) acrylate copolymer, at least one glidant, at least one plasticizer, and 1 to < 6% of at least one nonionic emulsifier based on the total weight of the pH responsive polymer composition.

The present disclosure discloses Lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and application thereof, which belongs to the technical field of microorganisms. The L. reuteri CCFM1132 can reduce serum uric acid levels of mice with hyperuricemia, inhibit the activity of serum and liver xanthine oxidase (XOD), and reduce the occurrence of hyperuricemia and gout; reduce serum creatinine levels, reduce serum total triglyceride (TG) levels, and inhibit the activity of serum alkaline phosphatase (ALP); and promote the expression of ileum uric acid transporter ABCG2. The L. reuteri CCFM1132 of the present disclosure can be used for preparing functional bacterial agents, food and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

The invention provides an ileum stoma auxiliary device. The ileum stoma auxiliary device is characterized by comprising a hollow tube body, an ostomy bag is mounted at the top of the tube body; a bottom disc extending outwards is arranged at the bottom end of the tube body, and a sewing ring is arranged on the upper surface of the bottom disc; a middle disc extending outwards is arranged in the middle of the tube body, and a sewing ring is arranged on the upper surface of the middle disc. Related complications after ileum stoma operation are reduced, and ileum stoma reduction operation is facilitated.

A gastrointestinal implant adapted to be implanted in a gastrointestinal structure such as a duodenum, a jejunum, and / or an ileum comprises a plurality of adjacent layers bonded to one another. One of more of the layers comprises at least one of a selected pore size and interpore distance, and at least one medicament is coupled to at least one medial surface of one or more layers to achieve one or more treatment goals selected from minimizing or alleviating trauma associated with implantation of the gastrointestinal sleeve, preventing or treating infection, treating eating disorders or conditions of the patient, treating one or more gastrointestinal tract structures exterior to or distal to at least a portion of the sleeve, or treating the patient's microbiome.

The invention discloses an ileum bladder expansion supporting drainage device which comprises an ileum supporting balloon, two ureter supporting balloons in one-to-one correspondence with two ureters, two ureter supports in one-to-one correspondence with the two ureters and a four-cavity catheter. According to the ileum bladder dilatation supporting drainage device, through cooperation of the four-cavity catheter, the ureter support, the ileum supporting balloon and the ureter supporting balloon, the ileum supporting balloon and the ureter supporting balloon are subjected to water filling expansion, so that the ileum supporting balloon supports the ileum, the ureter supporting balloon supports the ureter, the ureter is dilated, and the drainage effect is improved. Meanwhile, an anastomotic stoma between the ileum and the ureter is expanded, and the problem that the anastomotic stoma is narrow is solved; meanwhile, the ureter supporting balloon and the ileum supporting balloon have certain hardness after being inflated with water, the ureter supporting balloon plays a role in supporting the ureter stent after being inflated with water, and the ureter stent is prevented from moving and falling off.

The invention relates to the technical field of fistulization devices, in particular to an ileum fistulization device with a stoma monitoring function, which comprises a fixed chassis, a covering assembly and a monitoring assembly. The monitoring assembly comprises a fixing ring; an electrode plate and a photoelectric sensor are arranged at the bottom of the fixing ring; an electric control assembly is arranged on the fixing ring and electrically connected with the electrode plates and the photoelectric sensor through wires. According to the invention, leakage monitoring and ischemia early warning functions are integrated, tissue impedance can be measured through the electrode slice, and leakage can be accurately identified. Meanwhile, the photoelectric sensor is used for monitoring the blood oxygen saturation degree, the oppression ischemia condition can be found in time, and stoma tissue necrosis is prevented. According to the invention, seepage and ischemia states can be monitored in advance according to monitoring data, and the problem that detection and alarm can only be carried out after certain serious consequences are generated by a transmission monitoring device is avoided. The skin injury and infection risk caused by leakage or ischemia of a patient can be remarkably reduced, and the use comfort and life quality of the patient are improved.

The application discloses a pig breed disease resistance breeding screening method based on taurine cholate metabolic markers, and belongs to the technical field of animal breeding. The application effectively screens the breeding pigs with stronger intestinal barrier function by establishing a breeding standard based on the intestinal barrier function difference, especially taking the taurine cholate level as a key index, and improves the health level and production benefit of pigs. Compared with the prior art, the ileum villus height to crypt depth ratio of the breeding pig is increased by 25.3%, the mRNA relative expression amount of ZO-1 and other tight junction proteins is increased by 32.7%, the SIgA and IgG levels are increased by 38.5%, the health level of the pig is significantly improved, and the production benefit is increased by 15.6%.

This invention relates to the field of poultry feed technology, and more particularly to a diet for determining the loss of endogenous amino acids in poultry and its application. The diet provided by this invention, by mass percentage, comprises 12-14% total amino acids, 17-22% hydrolyzed casein, 16-20% glucose, 18-21.6% amylose, and 30-37.4% amylopectin, wherein the ratio of glucose to starch is 0.30-0.40, and the ratio of amylose to amylopectin is 0.55-0.65. This invention can effectively detect the loss of endogenous amino acids in the ileum of broilers while ensuring normal weight gain and digestive physiological status, thereby improving the accuracy of calculating standard ileal amino acid digestibility, helping to reduce the waste of protein feed resources in broilers, and achieving precision nutrition.

The invention discloses a double layered delayed-release hard capsules made by double dipping, that is by two consecutive dip molding steps with the same mold pin without removing the film, provided by the first dip molding step, from the mold pin between the two dip molding steps, but dipping the mold pin with this first film on the mold pin in the second dip molding step, each dip molding step is done with a different polymer melt, providing a double layered delayed-release capsule, which passes the stomach and the jejunum and opens in the ileum.

The invention discloses a preparation method and application of a sodium alginate microcapsule loaded with a curcumin-spirulina composite drug and piperine, and belongs to the technical field of pharmaceutical preparations. In the system, curcumin is loaded on spirulina through electrostatic force, and curcumin and piperine are jointly encapsulated in a sodium alginate gel microcapsule through a microfluidic system. The gel microcapsule system has an ileum targeting function, and can effectively protect the encapsulated composite drug from being eroded by gastric acid. After entering the small intestine, the system can realize step-by-step release of the drug; piperine in the gel is firstly released to inhibit the efflux effect of p-gp protein, and the curcumin-spirulina composite drug resides between small intestine villi and is slowly released. The characteristic of step-by-step release can effectively promote the absorption and utilization of curcumin, amplify the anti-oxidation and immune regulation ability of curcumin at the ileum part, and promote the repair of irradiation enteritis. The system has good biocompatibility, is low in cost and simple to manufacture, and has a wide prospect in the aspect of prevention and treatment of irradiation enteritis.

The invention discloses an application of ganoderic acid A as an intestinal farnesic acid X receptor (FXR) inhibitor in preparation of a product for preventing and / or treating hyperlipidemia. Molecular docking software is used for predicting that ganoderic acid A can be combined with FXR and occupies an active site of the FXR, and a possible amino acid binding site is a TYR (tyrosine) 369 amino acid residue; the application of a Caco2 cell model proves that the ganoderic acid A can penetrate through a cell membrane to be directly combined with the FXR in the cell; a surface plasmon resonance result proves that ganoderic acid A can competitively inhibit the combination of an FXR endogenous agonist and FXR so as to inhibit the activity of the FXR endogenous agonist. By inhibiting the activity of FXR, the ganoderic acid A can significantly inhibit the expression of intestinal FXR target gene ileum bile acid binding protein, fibroblast growth factor 15 and small heterodimer partner, and effectively improve C57BL / 6J mouse hyperlipidemia induced by high fat diet.

The application discloses a strain capable of promoting vitamin B 12 absorption and improving cognitive function, and application thereof, and belongs to the technical field of biotechnology. The application provides a Paraglactobacillus paracus CCFA1525, which is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 67380 and a preservation date of November 18, 2025. The Paraglactobacillus paracus CCFA1525 can up-regulate the expression of key proteins in the ileum, promote the absorption of vitamin B 12 , relieve nerve damage and cognitive impairment caused by sleep deprivation, and thus plays a significant neuroprotective role. Therefore, the Paraglactobacillus paracus CCFA1525 can be used for developing products with anti-nerve damage function, and is suitable for improving cognitive impairment caused by vitamin B 12 absorption disorder, and has good functional application prospect and industrial production potential. 12 ​

The application discloses a lactobacillus gasseri for relieving salmonella typhimurium infection and application thereof, and belongs to the technical field of microorganisms. The lactobacillus gasseri CCFM1307 screened by the application has the effect of relieving inflammation caused by salmonella typhimurium infection, specifically embodied in the following aspects: significantly relieving the symptom of weight loss of an individual infected with salmonella typhimurium, significantly relieving pathological damage of an ileum and a colon of the individual infected with salmonella typhimurium, significantly reducing the level of inflammatory cytokines in intestinal tissues of the individual infected with salmonella typhimurium, significantly increasing the content of short-chain fatty acids in feces, and reducing the relative abundance of Bacteroides in feces of the individual infected with salmonella typhimurium. The lactobacillus gasseri has great application prospects in preparation of drugs for preventing, treating and / or adjuvant treating inflammation caused by salmonella typhimurium infection.

The invention discloses a composite microecological preparation and a preparation method and application thereof.The composite microecological preparation is prepared from a composite strain mainly composed of bacillus velezensis, enterococcus faecium, lactobacillus acidophilus, saccharomyces cerevisiae boulardii and clostridium butyricum, the composite strain is fermented and then forms a microcapsule structure with sodium alginate and auxiliaries, and the microcapsule structure is prepared. The probability that viable bacteria reach the tail end of the ileum can be increased, and the effects of preventing and treating lawsonia intracellularis of the pigs, adjusting the balance of intestinal flora of the pigs and improving the immunity of the pigs are achieved under the synergistic effect of probiotic substances secreted by the viable bacteria.

A therapeutic or non-therapeutic method of inducing satiety in a mammal is described. The method comprises administering to the mammal a composition comprising microparticles, in which the microparticles comprise lipid contained within a gastric-resistant, ileal-sensitive, carrier configured for release of the lipid in the ileum, wherein the composition is administered 1-3 hours prior to a meal. The carrier is a protein, typically denatured or hydrolysed plant or dairy protein, that is polymerised to form a lipid containing shell or matrix.

The invention discloses a method for determining the digestibility of mineral element nutrients in pig feed. The method comprises the following steps: selecting a test pig of which the ileum tail end and the cecum tail end are provided with T-shaped fistula, and preparing a feed containing an indicator; test periods including a pre-test period, an excrement collection period, a cecum chyme collection period and an ileum chyme collection period are set, and the test pigs are fed with the prepared feed; in the collection period, respectively collecting a feed sample, an excrement sample, a cecum chyme sample and an ileum chyme sample; measuring the content of mineral elements and the content of indicators in the feed sample, the excrement sample, the cecum chyme sample and the ileum chyme sample; and calculating the apparent digestibility of the mineral elements at different parts of the pig digestive tract according to a formula.

The application discloses application of fangchinoline in prevention and treatment of salmonella infection. The fangchinoline is an isoquinoline alkaloid and is a host-directed therapy natural compound. The application discloses that the fangchinoline has a strong effect on treatment of salmonella infection diseases in vivo and in vitro, and the effect is specifically shown as that the fangchinoline can effectively reduce the bacterial amount of intracellular infection bacteria. The fangchinoline administration can significantly reduce the pathogenic bacteria load in the liver, spleen, colon, cecum and ileum of mice, and reduce the pro-inflammatory factor level of the organism. The safety in vivo and in vitro shows that the fangchinoline has no any toxic side effect under the test dose. In addition, the fangchinoline has significant synergistic antibacterial activity in combination with fluoroquinolones, which is shown as reduction of intracellular salmonella infection bacteria number and reduction of the pathogenic bacteria load in the liver, spleen and colon of mice. The application provides a new perspective for development of a new anti-infection drug, and also provides a new idea for prevention and control of the increasingly serious salmonella infection.